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Abstract 
A simple, accurate and cost effective RP-HPLC method is developed for simultaneous estimation of glimepiride 
(GLIM) and metformin (MET) at tablet dosage form using C-18 column (4.6 x 250mm, 5μ, 100 A˚) with a mobile phase 
composed of methanol: water (90:10% v/v) buffered with ortho phosphoric acid   at a flow rate of 1.0 mL/min (UV –
detection at 231 nm). The retention time of both drugs (GLIM & MET) are observed as 4.286 & 2.262 respectively. Human 
plasma spiking studies of both the API and the formulation at the concentration of (0.2µg/mL - 1µg/mL) for glimepiride 
and metformin (1µg/mL - 5µg/mL) expressed the standard correlation coefficients of 0.9998 & 0.9999 respectively for API 
and 0.9917 & 0.99 respectively for the tablet dosage form. The mean (%) recoveries of glimepiride and metformin are 
99.98 and 99.9% respectively. The % RSD below 0.5 shows the high precision of the proposed method. Assay studies 
revealed that 98.05% of purity is observed for glimepiride and 99.69 for metformin in a tablet dosage form. Human plasma 
spiking studies revealed that a minimal quantum of glimepiride had been bound with the plasma proteins compare to 
metformin in the tablet dosage form. The plain plasma chromatogram observed that there is absorption of the human 
plasma proteins, but there is no interference of drug in the   plasma matrix. The method was validated as per the ICH 
guidelines. 
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1. Introduction 
Glimepiride is a medium to long acting sulfonyl 
urea antidiabetic drug. The primary mechanism of action of 
glimepiride in lowering blood glucose appears to be 
dependent on stimulating the release of insulin from 
functioning pancreatic beta cells [1]. Glimepiride is 
chemically known as 3-ethyl -4- methyl –N-(4[N-(1r, 4r)-
4-methyl cyclohexylcarbamoyl) sulfamoyl] phenethyl)-2-
oxo-2, 5dihydro-1H-pyrrole-1-carboxamide (Figure 1). 
Metformin is an oral antidiabetic drug belongs to the 
biguanide class. It is a first line drug for the treatment of 
type2 diabetes. Metformin mechanism of action differs 
from other classes of oral hypoglycemic agents. Metformin 
decreases blood glucose levels by decreasing hepatic 
glucose production, decreasing intestinal absorption of 
glucose and improving insulin sensitivity by increasing 
peripheral glucose uptake and utilization [2]. Metformin is 
chemically identified as1-carbamimidamido-N, N-
dimethylmethanimidamide (Figure 2). Till date, all 
analytical methods described simultaneous determination 
of glimepiride and metformin in liquid chromatography [3], 
liquid chromatography-tandem mass spectrometry methods 
[4]. In the present investigation, we developed a simple, 
accurate, selective liquid chromatographic method for the 
simultaneous estimation of glimepiride and metformin in 
both API and pharmaceutical dosage form. This developed 
method is applied in the human plasma spiking studies. 
 
 
Figure 1: Chemical structure of Glimepiride 
 
 
Figure 2: Chemical structure of Metformin 
hydrochloride 
2. Experimental   
2.1 Chemicals and Reagents 
Glimepiride (GLIM) active pharmaceutical 
ingredient (API) is supplied by department of 
pharmaceutical analysis, JSS College of pharmacy, Ooty, 
India and Metformin (MET) API is obtained from yarrow 
chemicals, Mumbai, India. Compound Glimepiride and 
Metformin tablets (each tablet containing 0.2mg of GLIM 
and 500mg of MET) and the tablets are procured from 
Sanofi pharmaceuticals, India. The purity of glimepiride 
and metformin is determined by FT IR spectroscopy and 
thermogravimetric analysis. 
HPLC grade methanol and water is obtained from 
SD fine chemicals (India). Ortho phosphoric acid AR is 
procured from Merck (Germany). All other related 
chemicals which are utilized for the investigation were of 
analytical grade. 
2.2 HPLC instruments and analytical conditions 
Chromatographic separation is achieved by 
utilizing a Shimadzu 20 A liquid chromatographic system 
(Tokyo, Japan) equipped with 20 AT pump, C-18 column 
(250mmx4.6mm I.D; particle size 5µm) and a PDA 
detector (SPD-20A). The system is controlled by LC 
solutions software in a personal computer. The column 
temperature is maintained at 25+/-2
º
C. 
The mobile phase consisted of methanol and water 
(90:10v/v). The apparent pH is to be adjusted at 2.5 with 
orthophosphoric acid. The isocratic program is used. The 
flow rate of 1.0mL/min and the injection volume 20µL. 
Peak purity analysis is carried out over a wavelength range 
of 190nm – 400nm by the Shimadzu LC solution software. 
The detection wavelength is set at 215 nm because both the 
components have higher responses. 
2.3 Sample preparation 
For the system suitability conditions, 1:5 ratios 
have been adopted for the dilution of glimepiride and 
metformin. 10mg/mL of glimepiride and 50mg/mL of 
metformin is prepared by mobile phase in a 10mL 
volumetric flask. 5mL of diluent is added and sonicated to 
dissolve the contents. Finally the volume is made up to 
10mL using diluent (mobile phase). These solutions are 
protected from light by wrapping with aluminum foil and 
stored at 5
º
 C in the refrigerator. 
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The test sample solution is prepared from 
pulverized compounds of glimepiride and metformin 
tablets. A 10- tablet equivalent  mass corresponding to 0.2 
mg of GLIM and 500 mg of MET is weighed and dissolved 
in mobile phase (methanol: water -90:10v/v) in a 250mL 
volumetric flask. The volume is made up with mobile 
phase. After ultra-sonicated for 15 min, the mixture is 
centrifuged at 6000 rpm for 10 min. The supernatant was 
separated and transferred in to the HPLC instrument to be 
for analyzation. 
2.4 Validation of developed RP-HPLC method: 
As per the International conference of 
Harmonization guide lines, the developed method should 
be validated by assessing the parameters such as system 
suitability, specificity, accuracy, precision, linearity, limit 
of detection/quantization and assay were optimized. 
2.5 System suitability: 
2.5.1 Standard stock solution (Mixed stock) preparation: 
Glimepiride and Metformin standard solutions were 
prepared in the 1:3 ratios.  Glimepiride (0.2mg) and 
Metformin (1500mg) were transferred in to 10mL 
volumetric flask. Diluent (5mL) was added and sonicated 
to dissolve the contents. Finally the volume is made up to 
10mL using diluents.  The mixed standard solution was 
injected for 3 times. 
2.5.2 Acceptance criteria:  Tailing factor for the peaks due 
to GLIM and MET should not be more than 2 
Theoretical plates for the GLIM and MET peaks 
in standard solution should not be less than 2500 
2.6 Specificity: 
Glimepiride and Metformin standard solutions 
were prepared in the 1:3 ratios.  Glimepiride (0.2mg) and 
Metformin (1500mg) were transferred in to 10mL 
volumetric flask. Diluent (5mL) was added and sonicated 
to dissolve the contents. Finally the volume is made up to 
10mL using diluents. 
2.6.1 Preparation of Blank solution: HPLC grade water 
was used as blank 
2.6.2 Standard I solution preparation: Working samples 
were prepared at 2μg/mL & 6μg/mL of glimepiride and 
Metformin respectively. 
2.6.3 Standard II solution preparation: Working samples 
were prepared at 4μg/mL & 12μg/mL of glimepiride and 
metformin respectively. 
2.6.4 Standard III solution preparation: Working samples 
were prepared at 6μg/mL & 18μg/mL of glimepiride and 
metformin respectively. 
2.6.5 Procedure: The blank, standard I, standard II and 
standard III were injected in replicates 
2.7 Accuracy: 
Glimepiride and Metformin standard solutions 
were prepared in the 1:3 ratios.  Glimepiride (0.2mg) and 
Metformin (1500mg) were transferred in to 10mL 
volumetric flask. Diluent (5mL) was added and sonicated 
to dissolve the contents. Finally the volume is made up to 
10mL using diluents. 
2.7.1 Preparation of sample solutions: 
2.7.1.1 Preparation of 80% solution: For 80% level, 
working samples were prepared at 3μg/mL and 9μg/mL of 
glimepiride and metformin respectively (1:3 ratio of 
GLIM: MET) 
2.7.1.2 Preparation of 100% solution: For 100% level, 
working samples were prepared at 4μg/mL and 12μg/mL of 
glimepiride and metformin respectively (1:3 ratio of 
GLIM: MET) 
2.7.1.3 Preparation of 120% solution: For 120% level, 
working samples were prepared at 5μg/mL and 15μg/mL of 
glimepiride and metformin respectively (1:3 ratio of 
GLIM: MET) 
2.8 Precision: 
Glimepiride and Metformin standard solutions 
were prepared in the 1:3 ratios.  Glimepiride (0.2mg) and 
Metformin (1500mg) were transferred in to 10mL 
volumetric flask. Diluent (5mL) was added and sonicated 
to dissolve the contents. Finally the volume is made up to 
10mL using diluents. Working samples were prepared at 
6μg/mL and 18μg/mL of glimiperide and metformin 
respectively. The sample solution was injected for six times 
and measured the area for all six injections in HPLC. 
2.8.1 Acceptance criteria: The percentage (%) RSD for the 
area of six standard injections results should not be more 
than 2% 
2.9 Limit of detection (LOD) and Limit of Quantization 
(LOQ) 
The LOD and LOQ of glimepiride and metformin 
were determined on the basis of response and slope of the 
regression equation.LOD and LOQ values were calculated 
using the formula: LOD = 3σ/S & LOQ = 10σ/S 
Where σ = The standard deviation of the 
response; S = Slope of the calibration curve. 
2.10 Linearity: 
0.2mg of glimepiride and 1500mg of Metformin 
were weighed (1:3ratio) were weighed and transferred to 
10mL volumetric flask. 5mL of diluents was added and 
sonicated to dissolve the contents. Finally, the volume was 
made up of 10mL using diluents. Linearity range for 
glimiperide (1μg/mL - 5μg/mL) & metformin (5μg/mL - 
25μg/mL) respectively. 
2.11 Human Plasma spiking studies 
Interference of matrix effect on developed RP-
HPLC method is determined by spiking known 
concentrations of glimepiride and metformin in human 
plasma. Healthy human volunteers have been selected and 
briefed about the research. After briefing, blood samples 
are collected in the vacutiner mixed with sodium citrate 
(anticoagulant). The plasma has been separated in a cooling 
centrifuge (6000rpm) and stored in a cooling refrigerator 
maintaining the temperature at 2
º
 C +/- 1
º
 C for 48 hr and 
filtered through 0.22µm filter. Known concentrations of 
GLIM and MET are spiked in 200µL of plasma and 
incubated for 6hours. Later, plasma proteins are 
precipitated using methanol followed by centrifugation at 
6000 rpm in a cooling centrifuge. Methanol fractions are 
collected and purified by solid phase extraction cartridges 
(Oasis C18). Samples are concentrated and analyzed by 
RP-HPLC method. Linearity studies were carried out in the 
concentration range of GLIM (1-5µg/mL) and MET (5-
25µg/mL) performed in both API and formulation [5]. 
 
3. Results and discussion 
3.1 Method development 
An isocratic HPLC method is adopted to obtain a 
shorter run time and high sensitivity based on the polarity 
differences among GLIM and MET. A stainless steel 
column (250x4.6mm) is used for chromatographic 
conditions. To optimize the mobile phase, various 
combinations of buffer, methanol and water are studied in 
C18 column. Initially, combination of methanol: water 
(50:50) is used on trial basis for the separation of GLIM 
and MET in combined dosage form. It is found that the 
resolution is not satisfactory. On similar lines, various 
ratios of combinations of methanol and water are trialed for 
the resolution of GLIM and MET. The resolution effects 
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are not obtaining good shape. The combination of the 
solvents was modified by using methanol: water (80:20) 
found that the peaks with good shape and co-eluted at the 
RT2.393 & 4.427 for metformin and glimepiride 
respectively. A typical chromatogram for the method 
development is shown in Figure 3. 
 
Glimepiride RT: 4.392 & Metformin RT: 2.171  
Figure: 3 Chromatogram of Glimepiride and Metformin in methanol: water (80:20) 
 
3.2 Method Validation 
The proposed method is validated as per the ICH 
(International Conference of Harmonization) guidelines 
with the aspect of system suitability, specificity, linearity, 
accuracy, precision, LOD, LOQ and assay according to the 
ICH guidelines[6]. 
3.2.1 System suitability test: System suitability is 
determined by six replicate injections of the system 
suitability solution. The acceptance criteria  is less than 2% 
relative standard deviation for glimepiride  and metformin 
for peak areas, greater than 5000 column plates, less than 
1.5 of the USP tailing factor and greater than 1.5 of the 
resolution. The results obtained were all within the 
acceptable limits.  
3.2.2 Specificity: The selectivity of the method is 
confirmed by observing the potential interferences caused 
by the excipients of tablet formulation under stress 
conditions prescribed by the ICH [7]. The chromatograms 
of the excipients are confirmed in Figure 4. 
 
  
Figure 4: Chromatogram of the tablet excipients 
 
 
3.2.3 Accuracy and precision 
The accuracy of the method is assessed by 
recovery test. A known amount of each standard powder is 
added to the blank samples at a concentrations of each drug 
(0.8, 1.0 &1.2µg/mL for GLIM and 4, 5 &6µg/mL for 
MET) respectively. The samples are analyzed in triplicate 
using optimal conditions of RP-HPLC method and 
chromatograms are recorded in Figure 5. The 
corresponding percentage recovery data is summarized in 
Table 1. 
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Glimepiride – RT: 4.324 & Metformin –RT: 2.156 
 
Figure 5: Overlay representative chromatogram – Accuracy (80%, 100% and 120%) 
 
Table 1: Results of accuracy studies of glimepiride and metformin 
S. 
No 
Level Met Glim Glimepiride Recovery 
% of 
recovery 
Metformin Recovery 
% of 
recovery 
  
Area Area 
Actual Amt 
added   
Actual 
Amt added 
  
1 80 9732111 1985620 0.8 0.7959 99.48 4 4.002 100.05 
2 80 9624280 1980842 0.8 0.8048 100.6 4 4.011 100.27 
3 80 9691539 1993555 0.8 0.7992 99.9 4 3.986 99.65 
 
Avg 9682643.3 1986672.33 
 
0.7999 99.99 
 
3.99 99.99 
 Std. Devation    0.0037 0.4619  0.01141 0.2566 
          4 100 15510649 3179012 1 1.001 100.1 5 4.994 99.88 
5 100 15539415 3174113 1 0.999 99.9 5 5.002 100.04 
6 100 15539415 3174113 1 0.999 99.9 5 5.002 100.04 
 
Avg 15529826.3 3175746 
 
0.999 99.9 
 
4.999 99.98 
 Std. Devation 
   
0.001 0.1 
 
0.0037 0.07549 
          7 120 10688589 1903120 1.2 1.22 102 6 5.99 100 
8 120 15507955 3172643 1.2 1.25 104 6 6.25 104 
9 120 10647405 1929255 1.2 1.21 101 6 6.2 103 
 
Avg 12281316.33 2335006 
 
1.22 102 
 
6.14 102 
 Std. Devation 
   
0.01732 1.4207 
 
0.1126 1.8905 
 
Repeatability or intra-day precision is investigated 
by injecting six replicate of sample solution on the same 
day of the concentration of 5µg/mL and 25µg/mL of GLIM 
and MET respectively. Inter day precision is assessed by 
analyzing newly prepared sample solutions in triplicate 
over three consecutive days. % RSD values obtained at the 
peak areas of GLIM and MET on a single day (day1, n=6) 
are 0.35% and 0.47% respectively. RSD values on 
triplicate injections on three successive days (days 1-3, 
n=9) are 1.8% and 2.0% respectively. The results implied 
that the method developed was accurate for the 
determination. The results were summarized in Table 2. 
 
Table 2: Results of Inter & Intraday Precision 
Intra day 
S. No Concentration Glimepiride Metformin 
  
5µg/mL; 25µg/mL 
RT AREA RT AREA 
1 4.873 325069 2.368 1584325 
2 4.858 323544 2.369 1581402 
3 4.831 323671 2.36 1583274 
4 4.808 326604 2.358 1582188 
5 4.789 326504 2.356 1582320 
6 4.757 331270 2.342 1586010 
      
  Average 4.8193333 326110.33 2.358833 1583253.16 
  Std. Deviation 0 0 0 0 
  %CV 0 0 0 0 
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Inter day 
S. No Concentration Glimepiride Metformin 
 
5µg/mL; 25µg/mL 
RT AREA RT AREA 
1 4.431 647647 2.283 3267747 
2 4.429 655783 2.28 3293761 
3 4.427 659859 2.281 3313726 
4 4.436 661417 2.29 3319759 
5 4.444 660954 2.295 3322349 
6 4.44 663085 2.289 3336555 
     
 
Average 4.4345 658214.67 2.28633 3308982.83 
 
Std. Deviation 0 0 0 0 
 
%CV 0 0 0 0 
 
3.2.4 Linearity: The linearity is checked by analyzing 
five working solutions of GLIM over the concentrations 
range 1-5µg/mL and 5-25µg/mL for MET. The following 
results were obtained: y = 48594x+60058 (r
2
 =0.9999) for 
GLIM and y=22040x+332389 (r
2
 =0.9979) for MET, 
where y= peak area, x= concentration of solution; r
2
 = the 
square of determined correlation coefficient. The results 
indicate that the method is linear over the concentration 
range studied. The typical chromatogram and calibration 
curve are recorded in Figure.6. 
 
Glimepiride – RT :4.365  & Metformin –RT :2.257 
 
Figure 6: Linearity graph of glimepiride and metformin 
 
3.2.5 LOQ and LOD: The LOQs for GLIM and MET 
corresponding to a signal –to –noise ratio of 10 are 0.837 
µg/mL and 0.188µg/mL for GLIM and MET respectively. 
On similar lines, LODs corresponding to a signal – noise 
ratio of 3 are 0.27µg/mL and 0.01µg/mL respectively. 
3.2.6 Assay of GLIM and MET in tablets: Three 
batches of mixture tablets are analyzed using the developed 
method. Results obtained were satisfactory that the mean 
percentage found for GLIM and MET are in good 
agreement with the label claimed. The mean percentage 
found and the RSD values are mentioned in the Table.3. It 
is indicated that the proposed method could be adopted for 
the determination of GLIM and MET in compound tablets. 
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Table 3: Assay of Glimepiride and Metformin Tablets 
S. No 
Sample Area              
(Glimepiride)  
% of Assay of Glimepiride 
Sample Area 
( Metformin) 
% of Assay of Metformin 
1 577358 98.23 73967191 100.22 
2 566705 97.42 73919410 100.16 
3 576356 99.08 72661541 98.45 
4 561491 96.53 73720671 99.89 
5 573398 98.58 73845300 100.06 
6 572997 98.51 73328776 99.36 
Average 571384.166 98.05 73573814.83 99.69 
Standard area 1178435.5 
 
7475927.66 
 
Std. Deviation 
 
0 
 
0 
% RSD 
 
0 
 
0 
 
3.2.7 Human Plasma spiking studies: Linearity of 
GLIM and MET (both API and Formulation) is performed 
by the interference matrix effect by spiking the known 
concentration range of 0.2 -1µg/mL for glimepiride and 1-
5µg/mL for metformin in both API and formulation 
respectively. It is observed that quantitative linearity was 
obeyed in the above concentrations. The regression 
equations of concentration at peak levels were found to be 
y = 37719x (r
2
 = 0.9998) and y= 988439x (r
2
 = 0.999) for 
API of glimepiride and metformin respectively. Similarly, 
compound tablets shows a regression of concentration at 
peak levels y= 32451x (r
2
 = 0.9917) and y= 40006x (r
2
 = 
0.9953) for glimepiride and metformin respectively. The 
quantitative linearity graphs and chromatograms are been 
expressed in Figure 7. 
 
 
Figure 7: (i) HPLC overlay chromatogram of blank plasma extract (ii) HPLC overlay chromatogram of 
Glimepiride and Metformin (API) (iii) HPLC overlay chromatogram of Glimepiride and Metformin (formulation) 
(iv)  Linearity studies of glimepiride spiked in human plasma (v) Linearity studies of metformin spiked in human 
plasma 
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4. Conclusion 
An isocratic LC method is developed and validated 
for the analysis of glimepiride and metformin in tablet 
dosage forms. The results are highly specific and selective. 
It is observed in the interference of external matrix in 
human plasma studies revealed that there is absorption of 
plasma proteins in the glimepiride in the tablet dosage 
form. On the contrary, there is no interference of drugs 
(glimepiride and metformin) in plasma matrix in a pure 
active ingredient form. Hence the validated RP-HPLC 
method is simple, sensitive, precise and accurate for the 
simultaneous estimation studies in bioanalytical arena. 
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